var data={"title":"Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/contributors\" class=\"contributor contributor_credentials\">Talmadge E King, Jr, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/contributors\" class=\"contributor contributor_credentials\">Kevin R Flaherty, MD, MS</a></dd><dd><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/contributors\" class=\"contributor contributor_credentials\">Richard J Glassock, MD, MACP</a></dd><dd><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/contributors\" class=\"contributor contributor_credentials\">Bruce S Bochner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/contributors\" class=\"contributor contributor_credentials\">Helen Hollingsworth, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Feb 15, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Eosinophilic granulomatosis with polyangiitis (Churg-Strauss), abbreviated EGPA, which was previously called the Churg-Strauss syndrome (CSS) or allergic granulomatosis and angiitis, is a multisystem disorder characterized by chronic rhinosinusitis, asthma, and prominent peripheral blood eosinophilia [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/1-7\" class=\"abstract_t\">1-7</a>]. EGPA is classified as a vasculitis of the small and medium sized arteries, although the vasculitis is often not apparent in the initial phases of the disease.</p><p>The most commonly involved organ is the lung, followed by the skin. EGPA, however, can affect any organ system, including the cardiovascular, gastrointestinal, renal, and central nervous systems. Vasculitis of extrapulmonary organs is largely responsible for the morbidity and mortality associated with EGPA.</p><p>The clinical features and diagnosis of EGPA will be reviewed here. The epidemiology, pathogenesis, treatment, and prognosis of this disorder, as well as the approach to patients with vasculitis <span class=\"nowrap\">and/or</span> eosinophilia are discussed separately. (See <a href=\"topic.htm?path=epidemiology-pathogenesis-and-pathology-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)&quot;</a> and <a href=\"topic.htm?path=treatment-and-prognosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss\" class=\"medical medical_review\">&quot;Treatment and prognosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)&quot;</a> and <a href=\"topic.htm?path=overview-of-and-approach-to-the-vasculitides-in-adults\" class=\"medical medical_review\">&quot;Overview of and approach to the vasculitides in adults&quot;</a> and <a href=\"topic.htm?path=approach-to-the-patient-with-unexplained-eosinophilia\" class=\"medical medical_review\">&quot;Approach to the patient with unexplained eosinophilia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">CLINICAL FEATURES</span></p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Phases of disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical features of EGPA typically develop in several sequential phases, although these phases are not always clearly distinguishable [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/8,9\" class=\"abstract_t\">8,9</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prodromal phase &ndash; The prodromal phase occurs among individuals in the second and third decades of life and is characterized by atopic disease, allergic rhinitis, and asthma.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Eosinophilic phase &ndash; Features of the eosinophilic phase include peripheral blood eosinophilia and eosinophilic infiltration of multiple organs, especially the lung and gastrointestinal tract. Almost 40 percent of patients with EGPA present with pulmonary opacities, asthma, and peripheral eosinophilia prior to the development of a systemic vasculitis (polyangiitis) [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/8\" class=\"abstract_t\">8</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Vasculitic phase &ndash; In the third and fourth decades of life, a life-threatening systemic vasculitis of the medium and small vessels frequently occurs, and is often associated with vascular and extravascular granulomatosis [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/6\" class=\"abstract_t\">6</a>]. The vasculitic phase may be heralded by nonspecific constitutional symptoms and signs, especially fever, weight loss, malaise, and lassitude.</p><p/><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Asthma and lung disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Asthma is the cardinal clinical feature of EGPA and is present in more than 90 percent of patients [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/10,11\" class=\"abstract_t\">10,11</a>]. Asthma usually precedes the vasculitic phase by approximately 8 to 10 years [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/6,12\" class=\"abstract_t\">6,12</a>]. (See <a href=\"#H3\" class=\"local\">'Phases of disease'</a> above.)</p><p>EGPA is typically suspected in patients whose asthma is poorly controlled on moderate doses of inhaled glucocorticoids; many patients diagnosed with EGPA require frequent or long-term courses of systemic glucocorticoids to control their asthma. As the vasculitic phase begins, asthma severity and the number of exacerbations may increase. Rarely, the asthma symptoms lessen in the early stages of the vasculitic phase.</p><p>Prolonged treatment of asthma with glucocorticoid therapy may partially or totally suppress the usual clinical signs of untreated EGPA. The disease may therefore not become evident until glucocorticoids are reduced or stopped [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/13,14\" class=\"abstract_t\">13,14</a>].</p><p>Other pulmonary findings are reported in 50 to 70 percent and include pulmonary opacities with eosinophilia, pleural effusion (often eosinophilic), nodules that are rarely cavitary, and alveolar hemorrhage [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/3\" class=\"abstract_t\">3</a>]. In one series, venous thromboembolic disease was noted in 8 percent [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/10\" class=\"abstract_t\">10</a>]. </p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Upper airway and ear disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Ear, nose, and throat involvement, including serous otitis media, allergic rhinitis, nasal obstruction, recurrent sinusitis, and nasal polyposis, is reported in 70 to 85 percent patients with EGPA [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/10,15-19\" class=\"abstract_t\">10,15-19</a>]. In a series of 29 patients with EGPA, nasal polyposis was detected in 60 percent [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/16\" class=\"abstract_t\">16</a>]. Prior to the onset of eosinophilic infiltration of the lung or other organs, the characteristics of these patients overlap considerably with those associated with aspirin-exacerbated respiratory disease. (See <a href=\"topic.htm?path=chronic-rhinosinusitis-clinical-manifestations-pathophysiology-and-diagnosis#H4\" class=\"medical medical_review\">&quot;Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis&quot;, section on 'CRS with nasal polyposis'</a> and <a href=\"topic.htm?path=aspirin-exacerbated-respiratory-disease\" class=\"medical medical_review\">&quot;Aspirin-exacerbated respiratory disease&quot;</a>.)</p><p>Chronic serous otitis media and sensorineural hearing loss are occasionally seen in EGPA and likely reflect the severity of rhinosinusitis [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/17,20,21\" class=\"abstract_t\">17,20,21</a>]. Necrotizing lesions of the nasopharynx and upper airway are more characteristic of granulomatosis with polyangiitis (Wegener's), and are unusual in EGPA. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-granulomatosis-with-polyangiitis-and-microscopic-polyangiitis\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of granulomatosis with polyangiitis and microscopic polyangiitis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Skin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Skin involvement is one of the most common features of the vasculitic phase of EGPA. Half to two-thirds of patients with EGPA have skin lesions, which usually appear as tender subcutaneous nodules on the extensor surfaces of the arm, particularly the elbows, hands, and legs (<a href=\"image.htm?imageKey=PULM%2F52628\" class=\"graphic graphic_picture graphicRef52628 \">picture 1</a>) [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/3,22\" class=\"abstract_t\">3,22</a>]. Biopsy of these lesions usually reveals granulomas. The pathology of cutaneous EGPA is discussed in greater detail separately. (See <a href=\"topic.htm?path=epidemiology-pathogenesis-and-pathology-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss#H11\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)&quot;, section on 'Pathology'</a>.)</p><p>Skin lesions can also appear as a macular or papular erythematous rash or hemorrhagic lesions, including petechiae, palpable purpura, and extensive ecchymosis [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/23\" class=\"abstract_t\">23</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Cardiovascular</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cardiac involvement is one of the more serious manifestations of EGPA, accounting for approximately one-half of deaths attributable to EGPA [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/24,25\" class=\"abstract_t\">24,25</a>]. Clinical manifestations include clinical signs of heart failure or pericarditis and cardiac rhythm abnormalities [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/24,26-28\" class=\"abstract_t\">24,26-28</a>]. Patients with cardiac involvement typically have a shorter duration of EGPA related symptoms than those without. Cardiac involvement is more frequent in patients with higher eosinophil counts at the time of diagnosis [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/24,29\" class=\"abstract_t\">24,29</a>].</p><p>In a series of 383 patients with EGPA, 16 percent had a cardiomyopathy and 15 percent had pericarditis [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/10\" class=\"abstract_t\">10</a>]. In a separate series of 22 patients with evidence of cardiac involvement, cardiac abnormalities included an abnormal electrocardiogram (ECG) in all patients; valvular insufficiency, pericardial effusion, and heart failure were noted in 73, 50, and 41 percent, respectively [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/24\" class=\"abstract_t\">24</a>]. Endomyocardial involvement was found in 12 patients based on cardiac MRI findings of mural thrombus and a positive endomyocardial biopsy [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/24\" class=\"abstract_t\">24</a>]. The majority of patients improved with treatment, although 2 of the patients with endomyocardial disease died of heart failure. Patients with cardiac involvement were less likely to have a positive antineutrophil cytoplasmic antibody (ANCA) and more likely to have higher peripheral blood eosinophil counts than other EGPA patients.</p><p>The use of various cardiovascular tests to evaluate myocardial EGPA and the typical biopsy findings seen on endomyocardial biopsy are discussed separately. (See <a href=\"#H24\" class=\"local\">'Cardiovascular tests'</a> below and <a href=\"topic.htm?path=epidemiology-pathogenesis-and-pathology-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss#H11\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)&quot;, section on 'Pathology'</a>.)</p><p class=\"headingAnchor\" id=\"H280932879\"><span class=\"h2\">Thromboembolic disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with EGPA appear to be at increased risk for venous thromboembolism, similar to that seen in other systemic vasculitides. In a retrospective study of 232 patients with EGPA, the risk of venous thromboembolism (VTE) was 8 percent and did not differ significantly between those who were ANCA positive or not [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/30\" class=\"abstract_t\">30</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Neurologic</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A peripheral neuropathy, usually mononeuritis multiplex, is seen in up to 75 percent of patients with EGPA [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/3,6,27,31-35\" class=\"abstract_t\">3,6,27,31-35</a>]. Untreated, this may progress to a symmetric or asymmetric polyneuropathy [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/36\" class=\"abstract_t\">36</a>]. Severe neuropathic pain may accompany the peripheral neuropathy [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/33\" class=\"abstract_t\">33</a>]. A more detailed description of vasculitic neuropathy is presented separately. (See <a href=\"topic.htm?path=clinical-manifestations-of-vasculitic-neuropathy\" class=\"medical medical_review\">&quot;Clinical manifestations of vasculitic neuropathy&quot;</a>.)</p><p>In addition, EGPA-related central nervous system manifestations have been reported, including subarachnoid and cerebral hemorrhage, cerebral infarction, cranial nerve palsies, and loss of visual acuity [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/6,37-40\" class=\"abstract_t\">6,37-40</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Renal</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The frequency of renal involvement varies among studies [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/10,41,42\" class=\"abstract_t\">10,41,42</a>]. In the largest series of 383 patients with EGPA, renal involvement was found in 83 patients (22 percent) [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/10\" class=\"abstract_t\">10</a>]. Similar findings were noted in a series of 116 patients in which one-half had rapidly progressive or acute renal insufficiency (plasma creatinine concentration &gt;1.4 <span class=\"nowrap\">mg/dL</span> [&gt;124 <span class=\"nowrap\">micromol/L]),</span> while the others had isolated proteinuria or microscopic hematuria [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/42\" class=\"abstract_t\">42</a>]. Sixteen patients underwent renal biopsy, which demonstrated necrotizing glomerulonephritis in 11 patients. A positive test for ANCA was found in all patients with glomerulonephritis, compared with 26 percent of patients without renal involvement. (See <a href=\"#H17\" class=\"local\">'Antineutrophil cytoplasmic antibodies'</a> below.)</p><p>Systemic hypertension affects approximately 10 to 30 percent of patients with EGPA and may reflect renal involvement with EGPA or be a complication of glucocorticoid therapy [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/6,8,37\" class=\"abstract_t\">6,8,37</a>].</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Gastrointestinal tract</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>An eosinophilic gastroenteritis, characterized by abdominal pain (59 percent of patients), diarrhea (33 percent), gastrointestinal bleeding (18 percent), and colitis, may precede or coincide with the vasculitic phase of EGPA. (See <a href=\"topic.htm?path=eosinophilic-gastroenteritis\" class=\"medical medical_review\">&quot;Eosinophilic gastroenteritis&quot;</a> and <a href=\"#H3\" class=\"local\">'Phases of disease'</a> above.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Musculoskeletal</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Myalgias, migratory polyarthralgias, and frank arthritis are less common, but may affect 40 to 50 percent of patients in the vasculitic phase of the disorder [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/6\" class=\"abstract_t\">6</a>]. (See <a href=\"#H3\" class=\"local\">'Phases of disease'</a> above.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Lymphadenopathy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Eosinophilic lymphadenopathy has been noted in 30 to 40 percent of patients [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/14\" class=\"abstract_t\">14</a>]. Prominent cervical and axillary lymphadenopathy has been reported with individual lymph nodes up to 3 cm in diameter.</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Complications in pregnancy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The fetal death rate may be slightly increased among pregnancies occurring in patients with EGPA, although the number of reported pregnancies is low. As an example, one review reported a fetal death rate of approximately 15 percent among 22 pregnancies [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/3\" class=\"abstract_t\">3</a>]. The effect of EGPA on the placenta is not known.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">EVALUATION AND DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of EGPA is typically suspected based on the clinical findings (ie, eosinophilia <span class=\"nowrap\">&ge;1500/microL,</span> asthma, allergic rhinitis). However, confirming the diagnosis is often difficult because of the following confounding factors:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Individual manifestations of the syndrome can occur in isolation.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lung parenchymal involvement is not universal.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Some manifestations can exist for many years before additional features become clinically apparent. (See <a href=\"#H3\" class=\"local\">'Phases of disease'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Although EGPA is classified as a vasculitis, only 40 to 60 percent of patients with EGPA have antineutrophil cytoplasmic antibodies (ANCA). In addition, many biopsies do not show a necrotizing vasculitis or granuloma, but rather an apparently nondestructive infiltration of vessel walls by eosinophils [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/43\" class=\"abstract_t\">43</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-granulomatosis-with-polyangiitis-and-microscopic-polyangiitis\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of granulomatosis with polyangiitis and microscopic polyangiitis&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Laboratory tests</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are no laboratory tests that are specific for EGPA, although eosinophilia is characteristic. For patients who have suspected EGPA, we typically obtain a complete cell count with differential, a total eosinophil count, and an IgE level. We also usually obtain an ANCA test, although the sensitivity and specificity are low, as noted below.</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h3\">Eosinophilia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Peripheral blood eosinophilia (usually 5000 to 9000 <span class=\"nowrap\">eosinophils/microL)</span> is the most characteristic finding, although levels over 1500 <span class=\"nowrap\">cells/microL</span> (or greater than 10 percent of the total leukocyte count) should prompt suspicion for EGPA [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/8,44,45\" class=\"abstract_t\">8,44,45</a>]. Eosinophilia, however, is occasionally missed because of rapid spontaneous, or glucocorticoid-induced reductions or fluctuations in eosinophil counts. Tissue eosinophilia can still be found in patients in whom peripheral blood eosinophilia is absent.</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h3\">Antineutrophil cytoplasmic antibodies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>ANCA are found in 30 to 60 percent of patients with EGPA [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/11,12,31,46-48\" class=\"abstract_t\">11,12,31,46-48</a>]. The majority of ANCA-positive EGPA patients (70 to 75 percent) have antibodies directed against myeloperoxidase with a perinuclear staining pattern (called MPO-ANCA or P-ANCA) (<a href=\"image.htm?imageKey=NEPH%2F78968\" class=\"graphic graphic_picture graphicRef78968 \">picture 2</a>) [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/27,49-51\" class=\"abstract_t\">27,49-51</a>]. (See <a href=\"topic.htm?path=clinical-spectrum-of-antineutrophil-cytoplasmic-autoantibodies\" class=\"medical medical_review\">&quot;Clinical spectrum of antineutrophil cytoplasmic autoantibodies&quot;</a>.) </p><p>EGPA disease manifestations may differ between ANCA-positive and ANCA-negative patients, although confirmatory data are needed [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/9\" class=\"abstract_t\">9</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a series of 157 consecutive patients with EGPA, 49 (31 percent) were ANCA positive [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/11\" class=\"abstract_t\">11</a>]. ANCA-positivity was associated with weight loss, myalgias, arthralgias, biopsy-proven vasculitis, glomerulonephritis on biopsy, hematuria, leukocytoclastic capillaritis <span class=\"nowrap\">and/or</span> eosinophilic infiltration of the arterial wall on biopsy, and other renal disease. However, 18 percent of those with definite vasculitis were ANCA-negative. Mononeuritis multiplex was associated with systemic vasculitis and ANCA-positivity, although 22 percent of patients with mononeuritis multiplex were ANCA-negative. In terms of ANCA types, 96 percent were specific for myeloperoxidase and 4 percent were specific for proteinase-3.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Among 383 patients with EGPA, those who were ANCA-positive had clinical vasculitis manifestations, such as peripheral neuropathy or renal involvement, more frequently than ANCA-negative patients, but less frequently had cardiomyopathy [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/10\" class=\"abstract_t\">10</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a series of 112 patients with newly diagnosed EGPA, a positive ANCA at diagnosis was associated with renal involvement, peripheral neuropathy, and biopsy-proven vasculitis, whereas a negative ANCA was associated with heart disease and fever [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/48\" class=\"abstract_t\">48</a>].</p><p/><p class=\"headingAnchor\" id=\"H18\"><span class=\"h3\">Acute phase reactants</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Tests of inflammation such as the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are nonspecific and do not differentiate between flares of EGPA and infections (eg, sinusitis, pneumonia). Their usefulness in EGPA is unclear. (See <a href=\"topic.htm?path=acute-phase-reactants#H8\" class=\"medical medical_review\">&quot;Acute phase reactants&quot;, section on 'Clinical use'</a>.)</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h3\">Other laboratory tests</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with strongly suspected or known EGPA, additional tests are performed to assess the extent of disease, including a urinalysis, serum creatinine, and a serum troponin [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/52-55\" class=\"abstract_t\">52-55</a>].</p><p>Nonspecific laboratory abnormalities that may be observed in EGPA include [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/6,8\" class=\"abstract_t\">6,8</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Normochromic, normocytic anemia</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Leukocytosis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An elevated IgE level is common, and may vary with the activity of the vasculitic process</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypergammaglobulinemia</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A positive rheumatoid factor at low titer</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Normal or elevated complement (C3, C4, CH50) levels</p><p/><p class=\"headingAnchor\" id=\"H20\"><span class=\"h2\">Imaging</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Chest radiographs are typically obtained during a flare of asthma or to evaluate peripheral eosinophilia. Chest radiographic abnormalities in patients with EGPA are diverse and include the following (<a href=\"image.htm?imageKey=PULM%2F71677%7EPULM%2F59884\" class=\"graphic graphic_diagnosticimage graphicRef71677 graphicRef59884 \">image 1A-B</a>) [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/56-59\" class=\"abstract_t\">56-59</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Transient and patchy opacities (75 percent of patients), without lobar or segmental distribution</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Symmetrical opacities in an axillary and peripheral distribution</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Opacities radiating from the hilum with hilar adenopathy</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diffuse interstitial or miliary opacities</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pulmonary hemorrhage causing widespread shadowing</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bilateral, nodular disease without cavitation</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hilar adenopathy (infrequent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pleural effusions, which are found in 30 percent of patients, and are usually exudative and eosinophilic [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/57\" class=\"abstract_t\">57</a>]</p><p/><p>High resolution chest computed tomography (HRCT) is typically obtained to evaluate unexplained dyspnea, an abnormal chest radiograph, or gas transfer abnormalities, such as a low diffusion capacity or low pulse oximetry. Typical HRCT findings in EGPA include peribronchial thickening, areas of septal thickening, and widely scattered patchy, indistinct opacities. One series described parenchymal consolidation or ground glass opacification on the CT scans of 10 of 17 patients [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/59\" class=\"abstract_t\">59</a>]. These findings are not specific for EGPA, but may guide choice of a location for bronchoalveolar lavage or lung biopsy and help in the assessment of the extent of disease. (See <a href=\"topic.htm?path=high-resolution-computed-tomography-of-the-lungs\" class=\"medical medical_review\">&quot;High resolution computed tomography of the lungs&quot;</a>.)</p><p>A less common HRCT feature is a significant enlargement of the peripheral pulmonary arteries (when compared to the corresponding bronchi) in combination with a stellate and irregular configuration of some pulmonary arteries (referred to as the vasculitis sign) (<a href=\"image.htm?imageKey=PULM%2F73909\" class=\"graphic graphic_diagnosticimage graphicRef73909 \">image 2</a>) [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/58\" class=\"abstract_t\">58</a>].</p><p>Cardiac magnetic resonance imaging is discussed below. (See <a href=\"#H24\" class=\"local\">'Cardiovascular tests'</a> below.)</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h2\">Pulmonary function tests</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Spirometry typically shows variable airflow limitation (obstruction) consistent with asthma [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/8\" class=\"abstract_t\">8</a>]. Some patients may have a component of irreversible airflow limitation noted on spirometry or peak expiratory flow. When lung parenchymal involvement occurs, lung volume measurements (eg, total vital capacity and forced vital capacity) may be decreased. In addition, gas transfer abnormalities may be manifest by a low pulse oximetry at rest or with exertion, or by a decrease in the diffusion capacity. (See <a href=\"topic.htm?path=overview-of-pulmonary-function-testing-in-adults\" class=\"medical medical_review\">&quot;Overview of pulmonary function testing in adults&quot;</a> and <a href=\"topic.htm?path=pulmonary-function-testing-in-asthma\" class=\"medical medical_review\">&quot;Pulmonary function testing in asthma&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h2\">Bronchoalveolar lavage</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bronchoalveolar lavage (BAL) is typically performed in patients with interstitial opacities on radiographic imaging to evaluate for eosinophilia, infection, alveolar hemorrhage, or malignancy. In EGPA, BAL typically reveals a high percentage of eosinophils in the lavage fluid (usually greater than 33 percent). However, this finding is not specific for EGPA and would only be present in a patient with active pneumonitis (<a href=\"image.htm?imageKey=PULM%2F64886\" class=\"graphic graphic_table graphicRef64886 \">table 1</a>). (See <a href=\"topic.htm?path=causes-of-pulmonary-eosinophilia\" class=\"medical medical_review\">&quot;Causes of pulmonary eosinophilia&quot;</a> and <a href=\"topic.htm?path=role-of-bronchoalveolar-lavage-in-diagnosis-of-interstitial-lung-disease\" class=\"medical medical_review\">&quot;Role of bronchoalveolar lavage in diagnosis of interstitial lung disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H23\"><span class=\"h2\">Biopsy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Surgical lung biopsy, although not always available, is the &quot;gold standard&quot; for the diagnosis of EGPA [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/60\" class=\"abstract_t\">60</a>]. In contrast, transbronchial lung biopsy is generally not helpful. (See <a href=\"topic.htm?path=role-of-lung-biopsy-in-the-diagnosis-of-interstitial-lung-disease\" class=\"medical medical_review\">&quot;Role of lung biopsy in the diagnosis of interstitial lung disease&quot;</a>.)</p><p>When either skin disease or peripheral neuropathy is present, biopsy of one of those sites is less invasive and often preferred to a lung biopsy. In one study, 15 of 28 patients with a peripheral neuropathy and EGPA had evidence of a necrotizing vasculitis on a peripheral nerve biopsy [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/36\" class=\"abstract_t\">36</a>]. (See <a href=\"topic.htm?path=diagnosis-and-treatment-of-vasculitic-neuropathy\" class=\"medical medical_review\">&quot;Diagnosis and treatment of vasculitic neuropathy&quot;</a>.)</p><p>The lung biopsy from patients with EGPA may show asthmatic bronchitis, eosinophilic pneumonia, extravascular granulomas, or vasculitis (affecting arteries, veins, or capillaries). The histopathologic findings of EGPA are discussed in more detail separately. (See <a href=\"topic.htm?path=epidemiology-pathogenesis-and-pathology-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss#H11\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)&quot;, section on 'Pathology'</a>.)</p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h2\">Cardiovascular tests</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The specific indications for obtaining cardiovascular tests such as the ECG, echocardiogram, and cardiovascular magnetic resonance imaging (CMR) are unclear [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/26,61,62\" class=\"abstract_t\">26,61,62</a>]. We typically obtain an electrocardiogram and an echocardiogram (looking for wall motion abnormalities, mural thrombi, and valvular thrombi) as part of the initial evaluation of a patient with a diagnosis of EGPA even in the absence of symptoms suggesting cardiac disease. Approximately 40 percent of asymptomatic patients with a normal ECG have evidence of cardiac involvement with EGPA on echocardiogram [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/26\" class=\"abstract_t\">26</a>].</p><p>The most common echocardiographic finding in EGPA is wall motion abnormalities, which were found in 41 percent of patients in one case series [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/26\" class=\"abstract_t\">26</a>]. Other findings include valvular abnormalities (eg, mitral or aortic regurgitation), pericardial effusion, mural thrombi, and pulmonary hypertension.</p><p>If abnormalities are noted on ECG or echocardiogram, we perform CMR with gadolinium enhancement, if renal function is adequate. Gadolinium enhancement on CMR has been reported to correlate with endomyocardial biopsy evidence of eosinophilic infiltration [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/63\" class=\"abstract_t\">63</a>]. Assessment of late images may reveal myocardial necrosis or fibrosis [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/29,64\" class=\"abstract_t\">29,64</a>]. CMR may be a useful tool for EGPA risk stratification and treatment individualization [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/65,66\" class=\"abstract_t\">65,66</a>].</p><p>Gadolinium should be used with caution in patients with advanced renal insufficiency because of the risk of inducing nephrogenic systemic fibrosis. (See <a href=\"topic.htm?path=nephrogenic-systemic-fibrosis-nephrogenic-fibrosing-dermopathy-in-advanced-renal-failure\" class=\"medical medical_review\">&quot;Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure&quot;</a>.)</p><p>The exact sensitivity and specificity of CMR for myocardial involvement with EGPA is not known. A comparison of echocardiography and CMR in a small group of patients found that echocardiography had a sensitivity and specificity of 83 and 80 percent, respectively, for abnormalities on CMR, while CMR had a sensitivity and specificity of 88 and 72 percent, respectively, for echocardiographic abnormalities [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/26\" class=\"abstract_t\">26</a>]. </p><p>Fluoro-2-deoxyglucose-positron emission tomography (FDG-PET) has been evaluated as a method to determine whether delayed myocardial enhancement on CMR is due to fibrosis or inflammation. Among 14 patients with EGPA in remission and delayed myocardial enhancement on CMR, FDG-PET uptake was reduced in 10, increased in 2, and normal in 2 [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/67\" class=\"abstract_t\">67</a>]. FDG-PET uptake was also normal in six patients with normal CMR findings. As this study evaluated a small number of patients and the outcomes of alterations in therapy based on FDG-PET results were not assessed, further study is needed to determine the most appropriate role for FDG-PET in the evaluation of EGPA. &#160;</p><p>An endomyocardial biopsy is usually obtained when EGPA is suspected, the noninvasive testing suggests endomyocarditis, and the documentation of cardiac involvement would affect the decision about whether to initiate immunosuppressive therapy. (See <a href=\"topic.htm?path=endomyocardial-biopsy\" class=\"medical medical_review\">&quot;Endomyocardial biopsy&quot;</a> and <a href=\"topic.htm?path=epidemiology-pathogenesis-and-pathology-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss#H11\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)&quot;, section on 'Pathology'</a>.)</p><p class=\"headingAnchor\" id=\"H25\"><span class=\"h1\">DIAGNOSTIC CRITERIA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of different sets of criteria for the diagnosis of EGPA have been proposed [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/7,8,45,50,68\" class=\"abstract_t\">7,8,45,50,68</a>]. The classifications used most commonly are the American College of Rheumatology (ACR, preferred) and the Lanham criteria [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/8,45\" class=\"abstract_t\">8,45</a>].</p><p>The ACR has established six criteria for the classification of EGPA in a patient with documented vasculitis [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/45\" class=\"abstract_t\">45</a>]. The presence of four or more of these criteria had a sensitivity of 85 percent and a specificity of 99.7 percent for EGPA:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Asthma (a history of wheezing or the finding of diffuse high pitched wheezes on expiration)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Greater than 10 percent eosinophils on the differential leukocyte count</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mononeuropathy (including multiplex) or polyneuropathy</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Migratory or transient pulmonary opacities detected radiographically</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Paranasal sinus abnormality</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Biopsy containing a blood vessel showing the accumulation of eosinophils in extravascular areas (<a href=\"image.htm?imageKey=RHEUM%2F57180%7EPULM%2F82366\" class=\"graphic graphic_picture graphicRef57180 graphicRef82366 \">picture 3A-B</a>)</p><p/><p>The Lanham criteria include asthma, peak peripheral blood eosinophilia in excess of 1500 <span class=\"nowrap\">cells/microL,</span> and systemic vasculitis involving two or more extra-pulmonary organs [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/8\" class=\"abstract_t\">8</a>]. In this classification, all three criteria must be met for a diagnosis of EGPA.</p><p>A question that arises in the categorization of patients with suspected EGPA is how to classify patients with asthma and blood eosinophilia &gt;1500 <span class=\"nowrap\">cells/microL</span> <span class=\"nowrap\">and/or</span> &ge;10 percent of leukocytes, but without definite evidence of vasculitis outside the lungs, nose, and sinuses. One proposal is to reserve the designation of EGPA for patients with asthma and blood eosinophils &ge;1500 <span class=\"nowrap\">cells/microL</span> (1.5 <span class=\"nowrap\">G/L)</span> <span class=\"nowrap\">and/or</span> &ge;10 percent of leukocytes AND one or more of the following [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/11\" class=\"abstract_t\">11</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Definite polyangiitis: Biopsy showing necrotizing vasculitis, biopsy showing necrotizing or crescentic glomerulonephritis, alveolar hemorrhage, palpable purpura, or myocardial infarction due to proven coronaritis</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Definite surrogates for vasculitis: Hematuria associated with red cell casts or &gt;10 percent dysmorphic erythrocytes; hematuria with 2+ proteinuria; leukocytoclastic <span class=\"nowrap\">vasculitis/eosinophilic</span> infiltration of an arterial wall on biopsy</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mononeuritis or mononeuritis multiplex </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>ANCA and systemic manifestations (eg, myocarditis, pericarditis, peripheral neuropathy, other renal disease, abdominal pain)</p><p/><p>This proposal suggests creating a new category called &ldquo;hypereosinophilic asthma with systemic manifestations&rdquo; for patients with asthma, hypereosinophilia (&ge;1500 <span class=\"nowrap\">cells/microL</span> <span class=\"nowrap\">and/or</span> &ge;10 percent of leukocytes), and any systemic manifestation, but <strong>without</strong> ANCA, definite polyangiitis, a surrogate of polyangiitis, or mononeuritis. </p><p class=\"headingAnchor\" id=\"H26\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The main diseases to consider in the differential diagnosis of EGPA are aspirin-exacerbated respiratory disease, the eosinophilic pneumonias, allergic bronchopulmonary aspergillosis, the hypereosinophilic syndrome, granulomatosis with polyangiitis (Wegener's), and microscopic polyangiitis. The following observations may help to narrow the differential diagnosis:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Aspirin-exacerbated respiratory disease &mdash; Aspirin-exacerbated respiratory disease (AERD) refers to the combination of asthma, chronic rhinosinusitis with nasal polyposis, and reactions to <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> (acetylsalicylic acid, ASA) and other COX-1 inhibiting nonsteroidal antiinflammatory drugs (NSAIDs) characterized by bronchoconstriction, nasal congestion, and rhinorrhea. These patients may also have eosinophilia, but do not have eosinophilic pneumonia or the other organ system involvement seen in EGPA. However, AERD may evolve into EGPA [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/69\" class=\"abstract_t\">69</a>]. (See <a href=\"topic.htm?path=aspirin-exacerbated-respiratory-disease\" class=\"medical medical_review\">&quot;Aspirin-exacerbated respiratory disease&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chronic eosinophilic pneumonia &mdash; Chronic eosinophilic pneumonia usually lacks granulomas on biopsy and generally does not involve organs other than the lung [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/70,71\" class=\"abstract_t\">70,71</a>].</p><p/><p class=\"bulletIndent1\">Occasionally, an episode of eosinophilic pneumonia may precede the other manifestations of EGPA, making it difficult to differentiate EGPA from chronic eosinophilic pneumonia. These patients are monitored closely for development of evidence of additional organ involvement that would secure the diagnosis of EGPA. (See <a href=\"#H3\" class=\"local\">'Phases of disease'</a> above and <a href=\"topic.htm?path=causes-of-pulmonary-eosinophilia#H10\" class=\"medical medical_review\">&quot;Causes of pulmonary eosinophilia&quot;, section on 'Chronic eosinophilic pneumonia'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Allergic bronchopulmonary aspergillosis &mdash; Allergic bronchopulmonary aspergillosis is another cause of asthma, radiographic pulmonary opacities, and eosinophilia, but does not affect extrapulmonary organs other than the nose and sinuses. (See <a href=\"topic.htm?path=causes-of-pulmonary-eosinophilia\" class=\"medical medical_review\">&quot;Causes of pulmonary eosinophilia&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypereosinophilic syndrome &mdash; While some patients with the hypereosinophilic syndrome (HES) may have a cough, a minority have pulmonary infiltrates, and asthma is rare. When a clear differentiation cannot be made on clinical grounds, molecular testing for the <span class=\"nowrap\">FIP1L1/PDGFRalpha</span> mutation may be helpful as this is suggestive of HES. (See <a href=\"topic.htm?path=hypereosinophilic-syndromes-clinical-manifestations-pathophysiology-and-diagnosis#H25\" class=\"medical medical_review\">&quot;Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis&quot;, section on 'Hematologic evaluation'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Other vasculitides &mdash; Granulomatosis with polyangiitis, microscopic polyangiitis, and EGPA can all affect the lung, although the degree of eosinophilia and presence of asthma are typical of EGPA and not usually seen in the other two. The type of ANCA seen in EGPA is more typically anti-myeloperoxidase, whereas in granulomatosis with polyangiitis it is more likely anti-proteinase 3. (See <a href=\"topic.htm?path=overview-of-and-approach-to-the-vasculitides-in-adults\" class=\"medical medical_review\">&quot;Overview of and approach to the vasculitides in adults&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H27\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Eosinophilic granulomatosis with polyangiitis (Churg-Strauss), abbreviated EGPA, which was formerly called the Churg-Strauss syndrome (CSS) or allergic granulomatosis and angiitis, is a multisystem disorder characterized by chronic rhinosinusitis, asthma, and prominent peripheral blood eosinophilia (&ge; 1500 <span class=\"nowrap\">cells/microL</span> <span class=\"nowrap\">and/or</span> &gt;10 percent eosinophils on differential leukocyte count). The exact etiology of EGPA is unknown. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Asthma is the cardinal feature of EGPA (occurring in more than 95 percent of patients) and usually precedes the vasculitic phase by approximately 8 to 10 years. (See <a href=\"#H4\" class=\"local\">'Asthma and lung disease'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A peripheral neuropathy, usually mononeuritis multiplex, is seen in up to 75 percent of patients with EGPA. Central nervous system manifestations may include subarachnoid and cerebral hemorrhage, cerebral infarction, cranial nerve palsies, and loss of visual acuity. (See <a href=\"#H8\" class=\"local\">'Neurologic'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Two-thirds of EGPA patients have skin involvement ranging from palpable purpura to subcutaneous nodules. Skin biopsy is often helpful for confirming the diagnosis. (See <a href=\"#H6\" class=\"local\">'Skin'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cardiac involvement is one of the more serious manifestations of EGPA, accounting for approximately one-half of deaths attributable to EGPA. It should be suspected in the presence of refractory dyspnea, clinical evidence of heart failure, or cardiac rhythm abnormalities, but can also be asymptomatic. (See <a href=\"#H7\" class=\"local\">'Cardiovascular'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most patients with EGPA have peripheral blood eosinophilia (typically above <span class=\"nowrap\">1500/microL,</span> often 5000 to <span class=\"nowrap\">9000/microL),</span> although this may be obscured by use of systemic glucocorticoids to control asthma. (See <a href=\"#H16\" class=\"local\">'Eosinophilia'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antineutrophil cytoplasmic antibodies (ANCAs) are noted in 30 to 60 percent of EGPA patients. The majority of ANCAs associated with EGPA are directed against myeloperoxidase with a perinuclear staining pattern (called MPO-ANCA or P-ANCA). (See <a href=\"#H17\" class=\"local\">'Antineutrophil cytoplasmic antibodies'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Typical findings on chest high resolution computed tomography (HRCT) include patchy parenchymal consolidation or ground glass opacification; nodules may also be noted. (See <a href=\"#H20\" class=\"local\">'Imaging'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of EGPA is suggested by the presence of asthma, rhinosinusitis, and eosinophilia and then confirmed by lung biopsy or biopsy of other clinically affected tissues (eg, skin, peripheral nerve). (See <a href=\"#H14\" class=\"local\">'Evaluation and diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Two sets of diagnostic criteria are commonly used; the American College of Rheumatology (ACR) criteria for the classification of EGPA in a patient with documented vasculitis and the Lanham criteria. (See <a href=\"#H25\" class=\"local\">'Diagnostic criteria'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The main diseases to consider in the differential diagnosis of EGPA are aspirin-exacerbated respiratory disease, the eosinophilic pneumonias, allergic bronchopulmonary aspergillosis, the hypereosinophilic syndrome, granulomatosis with polyangiitis, and microscopic polyangiitis. (See <a href=\"#H26\" class=\"local\">'Differential diagnosis'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/1\" class=\"nounderline abstract_t\">CHURG J, STRAUSS L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 1951; 27:277.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/2\" class=\"nounderline abstract_t\">Churg A. Pulmonary angiitis and granulomatosis revisited. Hum Pathol 1983; 14:868.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/3\" class=\"nounderline abstract_t\">Sinico RA, Bottero P. Churg-Strauss angiitis. Best Pract Res Clin Rheumatol 2009; 23:355.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/4\" class=\"nounderline abstract_t\">Pagnoux C, Guilpain P, Guillevin L. Churg-Strauss syndrome. Curr Opin Rheumatol 2007; 19:25.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/5\" class=\"nounderline abstract_t\">Keogh KA, Specks U. Churg-Strauss syndrome. Semin Respir Crit Care Med 2006; 27:148.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/6\" class=\"nounderline abstract_t\">Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78:26.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/7\" class=\"nounderline abstract_t\">Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/8\" class=\"nounderline abstract_t\">Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984; 63:65.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/9\" class=\"nounderline abstract_t\">Pagnoux C, Guillevin L. Churg-Strauss syndrome: evidence for disease subtypes? Curr Opin Rheumatol 2010; 22:21.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/10\" class=\"nounderline abstract_t\">Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 2013; 65:270.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/11\" class=\"nounderline abstract_t\">Cottin V, Bel E, Bottero P, et al. Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): A study of 157 patients by the Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Autoimmun Rev 2017; 16:1.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/12\" class=\"nounderline abstract_t\">Cottin V, Khouatra C, Dubost R, et al. Persistent airflow obstruction in asthma of patients with Churg-Strauss syndrome and long-term follow-up. Allergy 2009; 64:589.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/13\" class=\"nounderline abstract_t\">Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998; 279:455.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/14\" class=\"nounderline abstract_t\">Churg A, Brallas M, Cronin SR, Churg J. Formes frustes of Churg-Strauss syndrome. Chest 1995; 108:320.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/15\" class=\"nounderline abstract_t\">Chumbley LC, Harrison EG Jr, DeRemee RA. Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Report and analysis of 30 cases. Mayo Clin Proc 1977; 52:477.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/16\" class=\"nounderline abstract_t\">Bacciu A, Buzio C, Giordano D, et al. Nasal polyposis in Churg-Strauss syndrome. Laryngoscope 2008; 118:325.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/17\" class=\"nounderline abstract_t\">Bacciu A, Bacciu S, Mercante G, et al. Ear, nose and throat manifestations of Churg-Strauss syndrome. Acta Otolaryngol 2006; 126:503.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/18\" class=\"nounderline abstract_t\">Srouji I, Lund V, Andrews P, Edwards C. Rhinologic symptoms and quality-of-life in patients with Churg-Strauss syndrome vasculitis. Am J Rhinol 2008; 22:406.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/19\" class=\"nounderline abstract_t\">Seccia V, Baldini C, Latorre M, et al. Focus on the Involvement of the Nose and Paranasal Sinuses in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Nasal Cytology Reveals Infiltration of Eosinophils as a Very Common Feature. Int Arch Allergy Immunol 2018; 175:61.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/20\" class=\"nounderline abstract_t\">Ishiyama A, Canalis RF. Otological manifestations of Churg-Strauss syndrome. Laryngoscope 2001; 111:1619.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/21\" class=\"nounderline abstract_t\">Nakamaru Y, Takagi D, Suzuki M, et al. Otologic and Rhinologic Manifestations of Eosinophilic Granulomatosis with Polyangiitis. Audiol Neurootol 2016; 21:45.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/22\" class=\"nounderline abstract_t\">Schwartz RA, Churg J. Churg-Strauss syndrome. Br J Dermatol 1992; 127:199.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/23\" class=\"nounderline abstract_t\">Kawakami T, Soma Y, Kawasaki K, et al. Initial cutaneous manifestations consistent with mononeuropathy multiplex in Churg-Strauss syndrome. Arch Dermatol 2005; 141:873.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/24\" class=\"nounderline abstract_t\">Neumann T, Manger B, Schmid M, et al. Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) 2009; 88:236.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/25\" class=\"nounderline abstract_t\">Corradi D, Maestri R, Facchetti F. Postpartum Churg-Strauss syndrome with severe cardiac involvement: description of a case and review of the literature. Clin Rheumatol 2009; 28:739.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/26\" class=\"nounderline abstract_t\">Dennert RM, van Paassen P, Schalla S, et al. Cardiac involvement in Churg-Strauss syndrome. Arthritis Rheum 2010; 62:627.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/27\" class=\"nounderline abstract_t\">Moosig F, Bremer JP, Hellmich B, et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis 2013; 72:1011.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/28\" class=\"nounderline abstract_t\">Mehta AK, Langford CA, Taylor DO, et al. A 39-Year-Old Postpartum Woman With Foot Drop and Shortness of Breath. Chest 2016; 149:e61.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/29\" class=\"nounderline abstract_t\">Szczeklik W, Miszalski-Jamka T, Mastalerz L, et al. Multimodality assessment of cardiac involvement in Churg-Strauss syndrome patients in clinical remission. Circ J 2011; 75:649.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/30\" class=\"nounderline abstract_t\">Allenbach Y, Seror R, Pagnoux C, et al. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis 2009; 68:564.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/31\" class=\"nounderline abstract_t\">Della Rossa A, Baldini C, Tavoni A, et al. Churg-Strauss syndrome: clinical and serological features of 19 patients from a single Italian centre. Rheumatology (Oxford) 2002; 41:1286.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/32\" class=\"nounderline abstract_t\">Solans R, Bosch JA, P&eacute;rez-Bocanegra C, et al. Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology (Oxford) 2001; 40:763.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/33\" class=\"nounderline abstract_t\">Wolf J, Bergner R, Mutallib S, et al. Neurologic complications of Churg-Strauss syndrome--a prospective monocentric study. Eur J Neurol 2010; 17:582.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/34\" class=\"nounderline abstract_t\">Santos-Pinheiro F, Li Y. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) presenting with polyneuropathy--a case series. J Clin Neuromuscul Dis 2015; 16:125.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/35\" class=\"nounderline abstract_t\">Cho HJ, Yune S, Seok JM, et al. Clinical Characteristics and Treatment Response of Peripheral Neuropathy in the Presence of Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Experience at a Single Tertiary Center. J Clin Neurol 2017; 13:77.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/36\" class=\"nounderline abstract_t\">Hattori N, Ichimura M, Nagamatsu M, et al. Clinicopathological features of Churg-Strauss syndrome-associated neuropathy. Brain 1999; 122 ( Pt 3):427.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/37\" class=\"nounderline abstract_t\">Liou HH, Liu HM, Chiang IP, et al. Churg-Strauss syndrome presented as multiple intracerebral hemorrhage. Lupus 1997; 6:279.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/38\" class=\"nounderline abstract_t\">Sheerin UM, Barreto J, Brown MM, et al. Subarachnoid haemorrhage as the first clinical manifestation of Churg-Strauss syndrome. J Neurol 2008; 255:607.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/39\" class=\"nounderline abstract_t\">Andr&eacute; R, Cottin V, Saraux JL, et al. Central nervous system involvement in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Report of 26 patients and review of the literature. Autoimmun Rev 2017; 16:963.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/40\" class=\"nounderline abstract_t\">Sabio JM, Rivero-Rodriguez M, Vargas-Hitos JA. Demographic and Clinical Characteristics Associated with Central Nervous System Hemorrhage in Patients with Eosinophilic Granulomatosis with Polyangiitis: A Case Report and Review of the Literature. J Rheumatol 2017; 44:1413.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/41\" class=\"nounderline abstract_t\">Clutterbuck EJ, Evans DJ, Pusey CD. Renal involvement in Churg-Strauss syndrome. Nephrol Dial Transplant 1990; 5:161.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/42\" class=\"nounderline abstract_t\">Sinico RA, Di Toma L, Maggiore U, et al. Renal involvement in Churg-Strauss syndrome. Am J Kidney Dis 2006; 47:770.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/43\" class=\"nounderline abstract_t\">Churg A. Recent advances in the diagnosis of Churg-Strauss syndrome. Mod Pathol 2001; 14:1284.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/44\" class=\"nounderline abstract_t\">Noth I, Strek ME, Leff AR. Churg-Strauss syndrome. Lancet 2003; 361:587.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/45\" class=\"nounderline abstract_t\">Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33:1094.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/46\" class=\"nounderline abstract_t\">Schmitt WH, Csernok E, Kobayashi S, et al. Churg-Strauss syndrome: serum markers of lymphocyte activation and endothelial damage. Arthritis Rheum 1998; 41:445.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/47\" class=\"nounderline abstract_t\">Reid AJ, Harrison BD, Watts RA, et al. Churg-Strauss syndrome in a district hospital. QJM 1998; 91:219.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/48\" class=\"nounderline abstract_t\">Sabl&eacute;-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005; 143:632.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/49\" class=\"nounderline abstract_t\">Nathani N, Little MA, Kunst H, et al. Churg-Strauss syndrome and leukotriene antagonist use: a respiratory perspective. Thorax 2008; 63:883.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/50\" class=\"nounderline abstract_t\">Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003; 115:284.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/51\" class=\"nounderline abstract_t\">Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005; 52:2926.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/52\" class=\"nounderline abstract_t\">Sidhu B, Nanda U, Abbas S. Is this an exacerbation of asthma? A cautionary tale. BMJ Case Rep 2013; 2013.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/53\" class=\"nounderline abstract_t\">McAleavey N, Millar A, Pendleton A. Cardiac involvement as the main presenting feature in eosinophilic granulomatosis with polyangiitis. BMJ Case Rep 2013; 2013.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/54\" class=\"nounderline abstract_t\">Hara T, Yamaguchi K, Iwase T, et al. Eosinophilic myocarditis due to Churg-Strauss syndrome with markedly elevated eosinophil cationic protein. Int Heart J 2013; 54:51.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/55\" class=\"nounderline abstract_t\">Kakouros N, Bastiaenen R, Kourliouros A, Anderson L. Churg-Strauss presenting as acute coronary syndrome: sometimes it's zebras. BMJ Case Rep 2011; 2011.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/56\" class=\"nounderline abstract_t\">Choi YH, Im JG, Han BK, et al. Thoracic manifestation of Churg-Strauss syndrome: radiologic and clinical findings. Chest 2000; 117:117.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/57\" class=\"nounderline abstract_t\">Erzurum SC, Underwood GA, Hamilos DL, Waldron JA. Pleural effusion in Churg-Strauss syndrome. Chest 1989; 95:1357.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/58\" class=\"nounderline abstract_t\">Buschman DL, Waldron JA Jr, King TE Jr. Churg-Strauss pulmonary vasculitis. High-resolution computed tomography scanning and pathologic findings. Am Rev Respir Dis 1990; 142:458.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/59\" class=\"nounderline abstract_t\">Worthy SA, M&uuml;ller NL, Hansell DM, Flower CD. Churg-Strauss syndrome: the spectrum of pulmonary CT findings in 17 patients. AJR Am J Roentgenol 1998; 170:297.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/60\" class=\"nounderline abstract_t\">Allen JN, Davis WB. Eosinophilic lung diseases. Am J Respir Crit Care Med 1994; 150:1423.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/61\" class=\"nounderline abstract_t\">Sauvetre G, Fares J, Caudron J, et al. [Usefulness of magnetic resonance imaging in Churg-Strauss syndrome related cardiac involvement. A case series of three patients and literature review]. Rev Med Interne 2010; 31:600.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/62\" class=\"nounderline abstract_t\">Marmursztejn J, Vignaux O, Cohen P, et al. Impact of cardiac magnetic resonance imaging for assessment of Churg-Strauss syndrome: a cross-sectional study in 20 patients. Clin Exp Rheumatol 2009; 27:S70.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/63\" class=\"nounderline abstract_t\">Baccouche H, Yilmaz A, Alscher D, et al. Images in cardiovascular medicine. Magnetic resonance assessment and therapy monitoring of cardiac involvement in Churg-Strauss syndrome. Circulation 2008; 117:1745.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/64\" class=\"nounderline abstract_t\">Mavrogeni S, Manoussakis MN, Karagiorga TC, et al. Detection of coronary artery lesions and myocardial necrosis by magnetic resonance in systemic necrotizing vasculitides. Arthritis Rheum 2009; 61:1121.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/65\" class=\"nounderline abstract_t\">Mavrogeni S, Karabela G, Gialafos E, et al. Cardiac involvement in ANCA (+) and ANCA (-) Churg-Strauss syndrome evaluated by cardiovascular magnetic resonance. Inflamm Allergy Drug Targets 2013; 12:322.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/66\" class=\"nounderline abstract_t\">Miszalski-Jamka T, Szczeklik W, Soko&#322;owska B, et al. Standard and feature tracking magnetic resonance evidence of myocardial involvement in Churg-Strauss syndrome and granulomatosis with polyangiitis (Wegener's) in patients with normal electrocardiograms and transthoracic echocardiography. Int J Cardiovasc Imaging 2013; 29:843.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/67\" class=\"nounderline abstract_t\">Marmursztejn J, Guillevin L, Trebossen R, et al. Churg-Strauss syndrome cardiac involvement evaluated by cardiac magnetic resonance imaging and positron-emission tomography: a prospective study on 20 patients. Rheumatology (Oxford) 2013; 52:642.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/68\" class=\"nounderline abstract_t\">Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37:187.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/69\" class=\"nounderline abstract_t\">Ameratunga R, Steele R. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss vasculitis) presenting as Samter's triad. J Allergy Clin Immunol Pract 2018; 6:280.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/70\" class=\"nounderline abstract_t\">Hueto-Perez-de-Heredia JJ, Dominguez-del-Valle FJ, Garcia E, et al. Chronic eosinophilic pneumonia as a presenting feature of Churg-Strauss syndrome. Eur Respir J 1994; 7:1006.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/abstract/71\" class=\"nounderline abstract_t\">Steinfeld S, Golstein M, De Vuyst P. Chronic eosinophilic pneumonia (CEP) as a presenting feature of Churg-Strauss syndrome (CSS). Eur Respir J 1994; 7:2098.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 4347 Version 21.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H27\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">CLINICAL FEATURES</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Phases of disease</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Asthma and lung disease</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Upper airway and ear disease</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Skin</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Cardiovascular</a></li><li><a href=\"#H280932879\" id=\"outline-link-H280932879\">Thromboembolic disease</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Neurologic</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Renal</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Gastrointestinal tract</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Musculoskeletal</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Lymphadenopathy</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Complications in pregnancy</a></li></ul></li><li><a href=\"#H14\" id=\"outline-link-H14\">EVALUATION AND DIAGNOSIS</a><ul><li><a href=\"#H15\" id=\"outline-link-H15\">Laboratory tests</a><ul><li><a href=\"#H16\" id=\"outline-link-H16\">- Eosinophilia</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">- Antineutrophil cytoplasmic antibodies</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">- Acute phase reactants</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">- Other laboratory tests</a></li></ul></li><li><a href=\"#H20\" id=\"outline-link-H20\">Imaging</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">Pulmonary function tests</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">Bronchoalveolar lavage</a></li><li><a href=\"#H23\" id=\"outline-link-H23\">Biopsy</a></li><li><a href=\"#H24\" id=\"outline-link-H24\">Cardiovascular tests</a></li></ul></li><li><a href=\"#H25\" id=\"outline-link-H25\">DIAGNOSTIC CRITERIA</a></li><li><a href=\"#H26\" id=\"outline-link-H26\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H27\" id=\"outline-link-H27\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PULM/4347|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/71677\" class=\"graphic graphic_diagnosticimage\">- EGPA (Churg-Strauss) PA</a></li><li><a href=\"image.htm?imageKey=PULM/59884\" class=\"graphic graphic_diagnosticimage\">- EGPA (Churg-Strauss) lateral</a></li><li><a href=\"image.htm?imageKey=PULM/73909\" class=\"graphic graphic_diagnosticimage\">- EGPA (Churg-Strauss) CT</a></li></ul></li><li><div id=\"PULM/4347|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/52628\" class=\"graphic graphic_picture\">- Skin ulceration EGPA (Churg-Strauss)</a></li><li><a href=\"image.htm?imageKey=NEPH/78968\" class=\"graphic graphic_picture\">- P-ANCA pattern on indirect immunofluorescence</a></li><li><a href=\"image.htm?imageKey=RHEUM/57180\" class=\"graphic graphic_picture\">- Small vessel vasculitis EGPA (Churg-Strauss)</a></li><li><a href=\"image.htm?imageKey=PULM/82366\" class=\"graphic graphic_picture\">- Lung biopsy EGPA (Churg-Strauss)</a></li></ul></li><li><div id=\"PULM/4347|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/64886\" class=\"graphic graphic_table\">- ILD associated BAL eosinophilia</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acute-phase-reactants\" class=\"medical medical_review\">Acute phase reactants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-patient-with-unexplained-eosinophilia\" class=\"medical medical_review\">Approach to the patient with unexplained eosinophilia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=aspirin-exacerbated-respiratory-disease\" class=\"medical medical_review\">Aspirin-exacerbated respiratory disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=causes-of-pulmonary-eosinophilia\" class=\"medical medical_review\">Causes of pulmonary eosinophilia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chronic-rhinosinusitis-clinical-manifestations-pathophysiology-and-diagnosis\" class=\"medical medical_review\">Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-granulomatosis-with-polyangiitis-and-microscopic-polyangiitis\" class=\"medical medical_review\">Clinical manifestations and diagnosis of granulomatosis with polyangiitis and microscopic polyangiitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-vasculitic-neuropathy\" class=\"medical medical_review\">Clinical manifestations of vasculitic neuropathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-spectrum-of-antineutrophil-cytoplasmic-autoantibodies\" class=\"medical medical_review\">Clinical spectrum of antineutrophil cytoplasmic autoantibodies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-and-treatment-of-vasculitic-neuropathy\" class=\"medical medical_review\">Diagnosis and treatment of vasculitic neuropathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=endomyocardial-biopsy\" class=\"medical medical_review\">Endomyocardial biopsy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=eosinophilic-gastroenteritis\" class=\"medical medical_review\">Eosinophilic gastroenteritis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-pathogenesis-and-pathology-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss\" class=\"medical medical_review\">Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=high-resolution-computed-tomography-of-the-lungs\" class=\"medical medical_review\">High resolution computed tomography of the lungs</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hypereosinophilic-syndromes-clinical-manifestations-pathophysiology-and-diagnosis\" class=\"medical medical_review\">Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nephrogenic-systemic-fibrosis-nephrogenic-fibrosing-dermopathy-in-advanced-renal-failure\" class=\"medical medical_review\">Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-and-approach-to-the-vasculitides-in-adults\" class=\"medical medical_review\">Overview of and approach to the vasculitides in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-pulmonary-function-testing-in-adults\" class=\"medical medical_review\">Overview of pulmonary function testing in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pulmonary-function-testing-in-asthma\" class=\"medical medical_review\">Pulmonary function testing in asthma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=role-of-bronchoalveolar-lavage-in-diagnosis-of-interstitial-lung-disease\" class=\"medical medical_review\">Role of bronchoalveolar lavage in diagnosis of interstitial lung disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=role-of-lung-biopsy-in-the-diagnosis-of-interstitial-lung-disease\" class=\"medical medical_review\">Role of lung biopsy in the diagnosis of interstitial lung disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prognosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss\" class=\"medical medical_review\">Treatment and prognosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)</a></li></ul></div></div>","javascript":null}